Logo
x

Search

Subscribe Now

Uterine Fibroids

PharmaShots Interview: Myovant's Dave Marek Shares Insights on the US FDA's Approval of Myfembree in Uterine Fibroids

PharmaShots Interview: Myovant's Dave Marek Shares Insights on the US FDA's Approval of Myfembree in Uterine Fibroids

  • July 20, 2021
Myovant's Ryeqo (relugolix- estradiol- and norethindrone acetate) Receives EC's Approval for the Treatment of Women with Uterine Fibroids

Myovant's Ryeqo (relugolix- estradiol- and norethindrone acetate) Receives EC's Approval for the Treatment of Women with Uterine F...

  • July 20, 2021
Pfizer and Myovant's Myfembree Receive the US FDA's Approval for Heavy Menstrual Bleeding Associated with Uterine Fibroids

Pfizer and Myovant's Myfembree Receive the US FDA's Approval for Heavy Menstrual Bleeding Associated with Uterine Fibroids

  • May 27, 2021
Pfizer and Myovant Report Results of Relugolix Combination Therapy in P-III LIBERTY Withdrawal Study in Women with Uterine Fibroids

Pfizer and Myovant Report Results of Relugolix Combination Therapy in P-III LIBERTY Withdrawal Study in Women with Uterine Fibroid...

  • March 25, 2021
Myovant and Pfizer Publish the Results of Relugolix Combination Regimen in P-III LIBERTY Studies in NEJM

Myovant and Pfizer Publish the Results of Relugolix Combination Regimen in P-III LIBERTY Studies in NEJM

  • February 18, 2021
AbbVie and Neurocrine's Oriahnn Receive the US FDA's Approval as the First Oral Therapy for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women

AbbVie and Neurocrine's Oriahnn Receive the US FDA's Approval as the First Oral Therapy for the Management of Heavy Menstrual Blee...

  • May 29, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.